Warnings and Precautions for Using Panobinostat

Panobinostat (Panobinostat) is a histone deacetylase inhibitor mainly used to treat multiple myeloma. Although it can have a positive impact on patient survival and quality of life in some cases, its use still requires patients and doctors to work closely together and pay attention to a series of warnings and precautions to ensure the safety and effectiveness of the treatment.

1. Heart Health Warning

Using panobinostat may cause cardiotoxicity, including heart problems such as irregular heartbeats. Therefore, before initiating treatment, patients should undergo a detailed cardiac evaluation, including an electrocardiogram and cardiac function tests. Patients require periodic cardiac monitoring during treatment, as well as more frequent monitoring at the beginning of treatment and after dose adjustments. Patients should notify their doctor immediately if they develop heart-related symptoms such as chest pain, palpitations, or shortness of breath.

2. Hematological toxicity

Use of panobinostat may result in hematologic toxicity, including anemia, thrombocytopenia, and leukopenia. During use, patients will need regular blood tests to monitor blood cell levels. If any abnormalities occur, your doctor may need to adjust the dose or take other steps to manage these adverse effects. Patients should be aware of any anemia-related symptoms, such as weakness, fatigue, and signs of easy bleeding or bruising that may be related to thrombocytopenia.

3. Liver function monitoring

The metabolism and elimination of panobinostat are mainly completed by the liver, so monitoring of liver function is crucial. Patients will need regular liver function tests during treatment to assess for signs of liver damage. If liver function abnormalities are found, your doctor may need to adjust the dose or pause treatment to prevent further damage.

4. Drug interactions

Pabinostat may interact with other drugs, especially those that may affect heart function or the blood system. Before starting treatment with panobinostat, patients should tell their doctor about all medications they are currently taking, including over-the-counter medications and supplements. Physicians will evaluate potential interactions based on the patient's medication history and adjust treatment to maximize safety.

5. Medication for Special Populations

1.Pregnant and lactating women: Pabinostat may cause fetal harm and is therefore contraindicated in pregnant women. Women should take effective contraceptive measures during treatment and continue to use contraceptive methods after treatment ends.

2.Elderly patients: Because elderly patients may be more susceptible to adverse reactions, the risks and benefits of panobinostat need to be carefully weighed and dosage adjustments may be necessary.

3.Children and Adolescents: The use of panobinostat in patients in this age group has not been fully studied and should be used with caution.

6. Gastrointestinal reactions

The use of panobinostat may cause some gastrointestinal effects, including nausea, vomiting, and diarrhea. Patients should inform their doctors of the occurrence of these symptoms so that timely symptomatic treatment can be provided to improve the patient's quality of life.

7. Things to note

1.Monitoring and follow-up: Patients need regular monitoring and follow-up during the use of panobinostat to ensure the effectiveness and safety of the treatment.

2.Follow the doctor's advice: Patients should strictly follow the doctor's advice and use panobinostat in accordance with the prescribed dosage and time.

3.Report symptoms promptly: Patients should pay attention to any new or worsening symptoms during treatment and report them to the doctor in time for timely intervention.

Taken together, the process of using panobinostat requires patients and doctors to work together and pay close attention to the patient's physical condition and treatment response. Regular monitoring, good communication, and timely adjustments will help ensure that panobinostat treatment is carried out under optimal conditions, providing patients with multiple myeloma with a better treatment experience and efficacy.

Panobinostat is not currently on the market in China, so patients cannot purchase it domestically and need to purchase panobinostat through overseas channels. There are only panobinostat original drugs available abroad, mainly the European version of the Swiss Novartis original drug, which is expensive, as high as more than 40,000 yuan.